drugset / Trial / NCT01370811

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

NCT01370811

Phase 2 Completed 24 enrolled Orient Pharma Co., Ltd.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine whether OC (oxybutynin and clonidine) oral solution is effective in reducing saliva secretion in patients suffering from Parkinson's Disease with excessive salivation.

Timeline

Start
2011-08
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Clonidine Other / unclassified Oral
Subject Oxybutynin Small molecule Oral

Indications

No indication recorded.